CymaBay Therapeutics, Inc. (CBAY)

8.55 +0.02 (+0.23%) At close: 04:00PM EST

CymaBay Therapeutics, Inc.

7575 Gateway Boulevard
Suite 110
Newark, CA 94560
United States
510 293 8800
https://www.cymabay.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 59

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Sujal A. Shah	Pres, CEO & Director	873.87k	N/A	1973
Dr. Dennis D. Kim M.B.A., M.D., MBA	Chief Medical Officer	406.11k	N/A	1970
Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA	Chief Commercial Officer	378.79k	N/A	1959
Mr. Daniel Menold	VP of Fin.	N/A	N/A	1970
Dr. Charles A. McWherter Ph.D.	Sr. VP, Pres of R&D and Chief Scientific Officer	N/A	N/A	1955
Mr. Paul T. Quinlan	Gen. Counsel, Chief Compliance Officer & Corp. Sec.	N/A	N/A	1963
Mr. Ken Boehm	Sr. VP of HR	N/A	N/A	N/A
Mr. Patrick J. O'Mara	Sr. VP of Bus. Devel.	N/A	N/A	1961
Dr. Robert L. Martin	Sr. VP of Manufacturing & Nonclinical Devel.	N/A	N/A	1962
Ms. Klara A. Dickinson-Eason	Chief Regulatory & Quality Assurance Officer	N/A	N/A	1968

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Corporate Governance

CymaBay Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 9. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.